Michael J. Stender

Dr. Michael J. Stender

Palliative Medicine | Hematology | Oncology
3577 West 13 Mile Road, Suite 404, 
Royal Oak, MI 
On Staff At
Accepting New Patients
Offers Telehealth
34 Years of Experience
3577 West 13 Mile Road, Suite 404, 
Royal Oak, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Stender is a Hematologist and a Palliative Medicine provider in Royal Oak, Michigan. Dr. Stender has been practicing medicine for over 34 years and is rated as an Experienced provider by MediFind in the treatment of Congenital Antithrombin 3 Deficiency. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Stender is currently accepting new patients.

His clinical research consists of co-authoring 10 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Wayne State University School Of Medicine, 1992
Residency
Indiana University Health
Specialties
Palliative Medicine
Hematology
Oncology
Licenses
Internal Medicine in MI
Board Certifications
American Board Of Internal Medicine
American Board Of Internal Medicine
American Board Of Internal Medicine
Fellowships
Indiana University Health
Hospital Affiliations
Corewell Health William Beaumont University Hospital
Corewell Health Beaumont Troy Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Cancer Care Associates
3577 West 13 Mile Road, Suite 404, Royal Oak, MI 48073

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)
Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)
Enrollment Status: Active_not_recruiting
Publish Date: October 30, 2025
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
View 6 Less Clinical Trials

10 Total Publications

Refractory Lactic Acidosis and Hypoglycemia in a Patient With Metastatic Esophageal Cancer Due to the Warburg Effect.
Refractory Lactic Acidosis and Hypoglycemia in a Patient With Metastatic Esophageal Cancer Due to the Warburg Effect.
Journal: Cureus
Published: June 17, 2023
Similar Doctors
Distinguished in Congenital Antithrombin 3 Deficiency
Dr. Seraphim Pallas
Hematology Oncology | Hematology | Oncology
Distinguished in Congenital Antithrombin 3 Deficiency
Dr. Seraphim Pallas
Hematology Oncology | Hematology | Oncology

Mclaren Oakland

5680 Bow Pointe Dr, Suite 202, 
Clarkston, MI 
 (17.4 miles away)
248-922-6650
Languages Spoken:
English, Greek
See accepted insurances
Accepting New Patients
Offers Telehealth

Seraphim Pallas is a Hematologist Oncology specialist and a Hematologist in Clarkston, Michigan. Dr. Pallas is rated as a Distinguished provider by MediFind in the treatment of Congenital Antithrombin 3 Deficiency. His top areas of expertise are Hereditary Resistance to Anti-Vitamin K, Congenital Antithrombin 3 Deficiency, Protein C Deficiency, Protein S Deficiency, and Bone Marrow Aspiration. Dr. Pallas is currently accepting new patients.

Advanced in Congenital Antithrombin 3 Deficiency
Dr. Sandeep K. Garg
Oncology | Hematology Oncology | Hematology
Advanced in Congenital Antithrombin 3 Deficiency
Dr. Sandeep K. Garg
Oncology | Hematology Oncology | Hematology

Henry Ford Health System

2799 W Grand Blvd, 
Detroit, MI 
 (11.7 miles away)
313-916-2600
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Sandeep Garg is an Oncologist and a Hematologist Oncology provider in Detroit, Michigan. Dr. Garg is rated as a Distinguished provider by MediFind in the treatment of Congenital Antithrombin 3 Deficiency. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Garg is currently accepting new patients.

Advanced in Congenital Antithrombin 3 Deficiency
Dr. Cortney V. Jones
Hematology Oncology | Hematology | Oncology
Advanced in Congenital Antithrombin 3 Deficiency
Dr. Cortney V. Jones
Hematology Oncology | Hematology | Oncology

Vhs Physicians Of Michigan

6071 W Outer Dr, Sgh Professional Office Bl, 
Detroit, MI 
 (6.8 miles away)
313-966-3116
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Cortney Jones is a Hematologist Oncology specialist and a Hematologist in Detroit, Michigan. Dr. Jones is rated as an Advanced provider by MediFind in the treatment of Congenital Antithrombin 3 Deficiency. His top areas of expertise are Breast Cancer in Men, Laryngeal Cancer, Familial Colorectal Cancer, Congenital Antithrombin 3 Deficiency, and Embolectomy. Dr. Jones is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stender's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 108 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile